Factors Associated with Absolute Neutrophil Count Dynamics and Docetaxel-Adryamicin-Cyclophosphamide (TAC) Chemotherapy Induced Neutropenia During Extended Filgrastim Administration in Breast Cancer Patients
Background: Myelosuppressive effects of chemotherapy for breast cancer treatment may trigger chemotherapy-induced neutropenia (CIN) and febrile neutropenia (FN). Filgrastim has been widely used as prophylaxis against CIN and FN. However despite filgrastim administration, some study showed FN still o...
Main Authors: | Ami Ashariati, Ugroseno Yudho Bintoro, Merlyna Savitri, Muhammad Noor Diansyah, Putu Niken Ayu Amrita, Pradana Zaky Romadhon, Andi Yasmin Wijaya, Winona May Hendrata, Steven Sheng Looi, Ahmad Amin Mahmudin |
---|---|
Format: | Article |
Language: | English |
Published: |
Interna Publishing
2022-07-01
|
Series: | Acta Medica Indonesiana |
Subjects: | |
Online Access: | https://actamedindones.org/index.php/ijim/article/view/1956 |
Similar Items
-
Filgrastim Induced Severe Leukocytosis in Sepsis-Associated Leukopenia: A Case Repor
by: Foroud Shahbazi, et al.
Published: (2019-07-01) -
Cost-effectiveness of pegfilgrastim versus filgrastim for prevention of chemotherapy-induced febrile neutropenia in patients with lymphoma: a systematic review
by: Girma Tekle Gebremariam, et al.
Published: (2022-12-01) -
Successful autologous stem cell collection with filgrastim and plerixafor after long-term lenalidomide therapy for multiple myeloma
by: Rishi Agarwal, et al.
Published: (2012-12-01) -
G-CSF filgrastim biosimilar-Sandoz reduces the incidence of febrile neutropenia in patients receiving chemotherapy regimens with rest periods not exceeding 14 days: A French, multicenter, prospective, non-interventional study
by: Jean-Marc Phelip, et al.
Published: (2023-01-01) -
Efficacy and Safety of Filgrastim and Its Biosimilars to Prevent Febrile Neutropenia in Cancer Patients: A Prospective Study and Meta-Analysis
by: Shruti Rastogi, et al.
Published: (2021-10-01)